반응식
[CH2:1]([C:3]1[CH:32]=[CH:31][CH:30]=[CH:29][C:4]=1[O:5][C:6]1[CH:11]=[CH:10][CH:9]=[CH:8][C:7]=1[C@:12]([C@@H:20]1[CH2:25][CH2:24][CH2:23][N:22]([C:26](Cl)=[O:27])[CH2:21]1)([OH:19])[CH2:13][CH2:14][CH2:15][CH2:16][O:17][CH3:18])[CH3:2].[NH2:33][CH2:34][CH:35]([OH:38])[CH2:36][NH2:37]>C(Cl)Cl>[CH2:1]([C:3]1[CH:32]=[CH:31][CH:30]=[CH:29][C:4]=1[O:5][C:6]1[CH:11]=[CH:10][CH:9]=[CH:8][C:7]=1[C@:12]([C@@H:20]1[CH2:25][CH2:24][CH2:23][N:22]([C:26]([NH:33][CH2:34][CH:35]([OH:38])[CH2:36][NH2:37])=[O:27])[CH2:21]1)([OH:19])[CH2:13][CH2:14][CH2:15][CH2:16][O:17][CH3:18])[CH3:2]참가 물질
반응물 2
생성물 1
시약·촉매·용매 1
실험 절차
To a solution of (R)-3-((S)-1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-methoxy pentyl)piperidine-1-carbonyl chloride (<0.05 mmol) in CH2Cl2, there was added excess 1,3-diaminopropan-2-ol (˜0.1 mL). The resulting solution was stirred at rt for 1 h, the CH2Cl2 was removed, and the residue was purified by prep HPLC to give (3R)-3-((S)-1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-methoxypentyl)-N-(3-amino-2-hydroxypropyl)piperidine-1-carboxamide (10.0 mg, 39%) as its TFA salt. 1H NMR (400 MHz, CD3OD): 7.64 (d, 1H), 7.32 (d, 1H), 7.04-7.20 (m, 4H), 6.74 (d, 1H), 6.56 (d, 1-H), 4.40 (d, 1H), 3.82 (m, 2H), 3.26 (t, 2H), 3.24 (s, 3H), 2.96 (m, 1H), 2.78 (m, 2H), 2.62 (q, 2H), 2.40 (m, 2H), 1.94 (m, 1H), 1.22-1.64 (m, 7H), 1.08 (t, 3H), 0.98 (m, 1H); MS m/z 514 (M+H+).
후처리
- customthe CH2Cl2 was removed
- customthe residue was purified by prep HPLC
출처 및 근거
- ORD 기록
- ord-be5bfef008bb4f5bbd19e50c85a2f680
- 출처 데이터셋
- uspto-grants-2011_01
- 특허 번호
- US07872028B2
연결된 노트
불러오는 중…